Bristol Myers Squibb delivered better than expected fourth quarter earnings, but Eliquis missed expectations while Cobenfy ...
Hosted on MSN
Zai Lab announces China NMPA approval for Cobenfy
Zai Lab (ZLAB) announced that China’s National Medical Products Administration approved the new drug application for Cobenfy for the treatment of schizophrenia in adults. The NMPA’s approval of ...
Myers' upcoming $30B patent cliff as the Growth portfolio lost significant potential. Read why BMY stock is downgraded to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results